Shining light on novel targets and therapies
- 13 December 2016
- journal article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 14 (2) , 75-76
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 studyThe Lancet Oncology, 2017
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung CancerJournal of Clinical Oncology, 2016
- NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancerOncotarget, 2016
- Nfib Promotes Metastasis through a Widespread Increase in Chromatin AccessibilityCell, 2016
- Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in PatientsCell Reports, 2016
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialThe Lancet Oncology, 2016
- CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancerJournal of Clinical Investigation, 2016
- A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivoScience Translational Medicine, 2015
- Comprehensive genomic profiles of small cell lung cancerNature, 2015
- Nuclear factor I/B is an oncogene in small cell lung cancerGenes & Development, 2011